Farmacologia/Analgesici oppioidi: differenze tra le versioni
Contenuto cancellato Contenuto aggiunto
Nessun oggetto della modifica |
Nessun oggetto della modifica |
||
Riga 48:
Anche i fenomeni di [[w:addiction|addiction]] agli oppioidi sono mediati dai recettori e ligandi μ, secondo alcuni studi preliminari la stimolazione del sottotipo 2 di questi induce i meccanismi di ricompensa, mentre quella del sottotipo 1 avversione come con gli agonisti κ, misurati mediante il test di place preference (Cooper 1991) , secondo alcuni mediante il rilascio secondario di κ-agonisti specifici. Non sono ancora perfettamente note le interazioni col sistema dopaminergico alla base della dipendenza da altre sostanze (Tokuyama 2000). Ancora allo stato iniziale sono anche gli studi sul sistema oppioide e la risposta allo stress, e a disturbi psichiatrici come ansia e depressione.
==Approfondimenti==
*Rasakham K, Liu-Chen LY. Sex differences in kappa opioid pharmacology. Life Sci. 2011 Jan 3; 88 (1-2) :2-16. PubMed PMID:20951148.
*Sakurada T, Mizoguchi H, Kuwahata H, Katsuyama S, Komatsu T, Morrone LA, Corasaniti MT, Bagetta G, Sakurada S. Intraplantar injection of bergamot essential oil induces peripheral antinociception mediated by opioid mechanism. Pharmacol Biochem Behav. 2011 Jan; 97 (3) :436-43. PubMed PMID:20932858.
*Chavkin C. The therapeutic potential of κ-opioids for treatment of pain and addiction. Neuropsychopharmacology. 2011 Jan; 36 (1) :369-70. PubMed PMID:21116263.
*Imai K, Koshiyama A, Nakata K. Towards clinical proteomics analysis. Biomed Chromatogr. 2011 Jan; 25 (1-2) :59-64. PubMed PMID:21121007.
*Hadjiconstantinou M, Neff NH. Nicotine and endogenous opioids: Neurochemical and pharmacological evidence. Neuropharmacology. 2010 Nov 22; PubMed PMID:21108953.
*Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ. 2010 Oct 26; 341:c5475. PubMed PMID:20978062; PubMed Central PMCID: PMC2965139.
*Lötsch J, Geisslinger G. Pharmacogenetics of new analgesics. Br J Pharmacol. 2010 Oct 13; PubMed PMID:20942817.
*Pani PP, Vacca R, Trogu E, Amato L, Davoli M. Pharmacological treatment for depression during opioid agonist treatment for opioid dependence. Cochrane Database Syst Rev. 2010 Sep 8; PubMed PMID:20824876.
*Frei MY, Nielsen S, Dobbin MD, Tobin CL. Serious morbidity associated with misuse of over-the-counter codeine-ibuprofen analgesics: a series of 27 cases. Med J Aust. 2010 Sep 6; 193 (5) :294-6. PubMed PMID:20819050.
*Singh I, Kumar P, Kumar S, Rana V. Formulation and development of matrix tablets of tramadol using katira gum as release modifier. Yakugaku Zasshi. 2010 Sep; 130 (9) :1225-31. PubMed PMID:20823680.
Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep. 2010 Aug; 7 (3) :152-60. PubMed PMID:20532839; PubMed Central PMCID: PMC2892618.
Borgeat A. Do opioids affect the ability to drive safely?. J Pain Palliat Care Pharmacother. 2010 Jun; 24 (2) :167-9. PubMed PMID:20504144.
Garnock-Jones KP, McKeage K. Methylnaltrexone. Drugs. 2010 May 7; 70 (7) :919-28. PubMed PMID:20426500.
von Gunten CF, Bruera E, Pirrello RD, Portenoy RK. New opioids: expensive distractions or important additions to practice?. J Palliat Med. 2010 May; 13 (5) :505-11. PubMed PMID:20406105.
Bandelow B, Schmahl C, Falkai P, Wedekind D. Borderline personality disorder: a dysregulation of the endogenous opioid system?. Psychol Rev. 2010 Apr; 117 (2) :623-36. PubMed PMID:20438240.
Smith HS. Opioid metabolism. Mayo Clin Proc. 2009 Jul; 84 (7) :613-24. PubMed PMID:19567715; PubMed Central PMCID: PMC2704133.
Vucković S, Prostran M, Ivanović M, Dosen-Mićović Lj, Todorović Z, Nesić Z, Stojanović R, Divac N, Miković Z. Fentanyl analogs: structure-activity-relationship study. Curr Med Chem. 2009; 16 (19) :2468-74. PubMed PMID:19601792.
Stein C, Zöllner C. Opioids and sensory nerves. Handb Exp Pharmacol. 2009; PubMed PMID:19655116.
Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009; 48 (11) :689-723. PubMed PMID:19817501.
Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002 Jul-Aug; 18 (4 Suppl) :S3-13. PubMed PMID:12479250.
[[Categoria:Farmacologia]]
| |||